AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06365853
Drug: Brimonidine tartrate ophthalmic solution eye drops
RxNorm normalized name: brimonidine tartrate Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Self-administration of brimonidine tartrate ophthalmic solution eye drops as prescribed by the treating physician.
Trial: NCT06346522
Drug: Gabapentin (Gaptin ®) 400mg oral capsule once
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the patient will regain feeding, the patients will take with sips of water Gabapentin (Gaptin ®) 400mg oral capsule once in the first 24 hour after icu admission
Trial: NCT06346522
Drug: Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule
RxNorm normalized name: trospium chloride 60 MG
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the patient will regain feeding, the patients will take with sips of water Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule once in the first 24 hour after icu admission
Trial: NCT06064097
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06064097
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06216301
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
Trial: NCT06216301
Drug: Platinum based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer
Trial: NCT06207305
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by PO
Trial: NCT06207305
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06207305
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06207305
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO
Trial: NCT06434363
Drug: Tafasitamab
RxNorm normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by vein (IV)
Trial: NCT06434363
Drug: Fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by vein (IV)
Trial: NCT05308940
Drug: TB001
RxNorm normalized name: CTB001
DrugBank: CTB001 (DB18316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once-daily subcutaneous injection, on Day 1 in SAD stage
Trial: NCT05308940
Drug: TB001
RxNorm normalized name: CTB001
DrugBank: CTB001 (DB18316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once-daily subcutaneous injection, on Days 1-7 in MAD stage
Trial: NCT05364021
Drug: LP352
RxNorm normalized name: Linzagolix
DrugBank: Linzagolix (DB17083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LP352 administered three times daily, orally or through G-tube
Trial: NCT05088655
Drug: Hetrombopag Olamine Tablet
RxNorm normalized name: Eltrombopag Olamine
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hetrombopag Olamine Tablet (T: test formulation) Hetrombopag Olamine Tablet (R: reference formulation)
Trial: NCT04768907
Drug: MaaT013
RxNorm normalized name: MaaT013
DrugBank: MaaT013 (DB18648)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06575933
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration
Trial: NCT06575933
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT00002243
Drug: Calanolide A
RxNorm normalized name: Calanolide A
DrugBank: Calanolide A (DB04886)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04842825
Drug: Er Zhi Wan combined with Si Wu Tang
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The TCM medicines used will be Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 20 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 12 g, Radix Yam 20 g. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening, for 10-15 days. According to follicular development and endometrial growth monitored by ultrasound, the herbs will be changed to Curculus 10 g, Xianling spleen 15 g, Morinda officinalis 15 g, Cuscutae 20 g, Amethyst 15 g, Rehmannia 20 g, Angelica 15 g, Chuanxiong 10 g，which will be taken for 10-15days.~After ET, the treatment group will continue to take Chinese herbal medicine, changing to Cuscuta 15 g, Sambucus 15 g, Chuan Guan Gong 10 g, Agaricus 9 g, Shu Di 15 g, Angelica 10 g, Bai Shao 12 g for 14 days
Trial: NCT04842825
Drug: Recombinant Human Follitropin Alfa 、Fructose 、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control group will be treated with conventional Western medicine（The specific drug dose is determined according to the individual level of patients）
Trial: NCT04809103
Drug: cis-diamminedichloroplatinum
RxNorm normalized name: CIS-DIAMMINEDICHLOROPLATINUM
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin delivered bronchoscopically at the time of diagnosis of NSCLC
Trial: NCT05918640
Drug: Lurbinectedin
RxNorm normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days. Doses will be determined in the phase 1 portion of the trial.
Trial: NCT04790136
Drug: GLA-015
RxNorm normalized name: GLA
DrugBank: Gamolenic acid (DB13854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration followed by PK blood sampling
Trial: NCT04790136
Drug: DAC C-052 Cannabidiol / NRF 22.10 Oily cannabidiol solution 100 mg/ml
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: administration followed by PK blood sampling
Trial: NCT05377788
Drug: Lazertinib
RxNorm normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of EGFR T790M mutant-positive local progressive or metastatic non-small cell lung cancer patients who have previously been treated with EGFR
Trial: NCT06369155
Drug: Azenosertib
RxNorm normalized name: Azenosertib
DrugBank: Azenosertib (DB18028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wee1 inhibitor, 25mg and 100mg tablets, taken orally per protocol.
Trial: NCT04817826
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).
Trial: NCT04817826
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tremelimumab 300 mg single administration (day 1)
Trial: NCT05753189
Drug: Aceclidine+Brimonidine combination ophthalmic solution
RxNorm normalized name: brimonidine Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combination ophthalmic solution of Aceclidine and Brimonidine
Trial: NCT05753189
Drug: Aceclidine Ophthalmic Solution
RxNorm normalized name: Aceclidine
DrugBank: Aceclidine (DB13262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclidine
Trial: NCT05817708
Drug: CX-4945
RxNorm normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: CX-4945~Silmitasertib, orally, once or twice daily for 5 days.~Other Name: Silmitasertib
Trial: NCT05194358
Drug: Stabilized Isoamyl Nitrite (SIAN)
RxNorm normalized name: isoamyl cinnamate
DrugBank: Amyl Nitrite (DB01612)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SIAN is comprised of isoamyl nitrite (IAN) stabilized with 4% by weight epoxidized linseed oil (ELSO) and administered by intranasal (IN) delivery as a nasal spray.~A syringe-based spray device will be used to administer the SIAN product. This syringe-based spray device, consists of a Hamilton type syringe connected to a tip that functions as an atomizer, to provide an optimal spray plume for nasal absorption while minimizing exposure to lungs.
Trial: NCT06223516
Drug: Subcutaneous (SC) ABBV-383
RxNorm normalized name: Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383
DrugBank: TNB-383B (DB17268)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC Injection
Trial: NCT06223516
Drug: Intravenous (IV) ABBV-383
RxNorm normalized name: Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383
DrugBank: TNB-383B (DB17268)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT05056194
Drug: Valiloxybate
RxNorm normalized name: Valiloxybate
DrugBank: Valiloxibic acid (DB16937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XW10172 MR Granules for Oral Suspension
Trial: NCT05308654
Drug: ABBV-453
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral; Tablet
Trial: NCT05308654
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Tablet
Trial: NCT05308654
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous Injection
Trial: NCT05308654
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Capsule
Trial: NCT06269146
Drug: Pramipexole Pill
RxNorm normalized name: pramipexole Pill
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study drug, pramipexole, is an FDA-approved medication for the treatment of Parkinson's and restless leg syndrome. Pramipexole (Mirapex) tablets are taken orally, with or without food.
Trial: NCT05700721
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO
Trial: NCT05700721
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT05488847
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: preoperative and discharge pain medication given to all patients
Trial: NCT05488847
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: preoperative pain medication given to all patients
Trial: NCT05488847
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative and discharge pain medication given to all patients
Trial: NCT05488847
Drug: Tizanidine
RxNorm normalized name: Tizanidine
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discharge pain medication given to all patients
Trial: NCT05488847
Drug: Magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Discharge pain medication given to all patients
Trial: NCT05488847
Drug: Oxycodone Hydrochloride 5 Mg
RxNorm normalized name: oxycodone hydrochloride 5 MG
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Only given to active comparator group
Trial: NCT06316960
Drug: Avapritinib
RxNorm normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd, d1-28.
Trial: NCT05671991
Drug: Empagliflozin 25 mg vs Placebo
RxNorm normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7
Trial: NCT06316960
Drug: Azacitidine Injection
RxNorm normalized name: azacitidine Injection
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 75mg/m2/d for weighing \>10kg, 2.5mg/kg/d for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.
Trial: NCT06316960
Drug: Decitabine Injection
RxNorm normalized name: decitabine Injection
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg/m2/d for weighing \>10kg, 0.67mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.
Trial: NCT06316960
Drug: Idarubicin Hydrochloride
RxNorm normalized name: Idarubicin Hydrochloride
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg/m2/day for weighing \>10kg, 0.17mg/kg/day for weighing ≤ 10kg, d 6, 8, 10 (d 8, 10, 12 for azacitidine) ivgtt, qod, more than 1 hour at 10 am.
Trial: NCT05671991
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chronic Study- Empagliflozin 10 mg for 8 weeks
Trial: NCT06316960
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg/m2/day for weighing \>10kg, 0.33mg/kg/day for weighing ≤ 10kg, d6-15 （d8-17 for azacitidine ）, s.c., q12h.
Trial: NCT06316960
Drug: Granulocyte Colony-Stimulating Factor
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300ug/day for weighing \>10kg, 10ug/kg/day for weighing ≤10kg, d0-5, s.c., qd.
Trial: NCT04991116
Drug: TILD sub-cutaneous (SC) injection
RxNorm normalized name: DAB(SUB 389)IL2
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mL injection of study medication
Trial: NCT05436522
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
Trial: NCT05436522
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
Trial: NCT03362736
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All participants will receive a single intravenous (IV) tiered dose of ustekinumab based on body weight at Week 0 (participants less than or equal to \[\<=\] 55 kilogram \[kg\] will receive 260 milligram \[mg\] ustekinumab; \> 55 kg to \<= 85 kg will receive 390 mg ustekinumab; and \> 85 kg will receive 520 mg ustekinumab infusion) during induction period. After the IV induction dose, all participants will receive the first maintenance dose of 90 mg ustekinumab subcutaneous (SC) injection 8 weeks later (Week 8). The participants with adequate response based on the physician's judgement will be subsequently treated with 90 mg ustekinumab SC injection with every 12 weeks through Week 80 and participants with an inadequate response to ustekinumab dosing every 12 weeks based on the physician's judgement will be subsequently treated with 90 mg of ustekinumab every 8 weeks through Week 80.
Trial: NCT05975463
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hepatic artery infusion of Adebrelimab 1200mg, d1, q3w，for 3-4 times.
Trial: NCT05975463
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: hepatic artery infusion of Bevacizumab 5mg/kg, d1, q3w, for 3-4 times.
Trial: NCT06486441
Drug: Sacituzumab govitecan-hziy
RxNorm normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously
Trial: NCT06486441
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT06523621
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 cycles of nivolumab at a dose of 480 mg given over approximately 30-minutes intravenously on Day 1 of each treatment cycle
Trial: NCT05839041
Drug: AVD-104
RxNorm normalized name: Avdoralimab
DrugBank: Avdoralimab (DB16392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection
Trial: NCT05839041
Drug: Avacincaptad
RxNorm normalized name: AVACINCAPTAD
DrugBank: Avacincaptad pegol (DB15165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 2 mg avacincaptad
Trial: NCT05155046
Drug: 18F-DCFPyL
RxNorm normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-DCFPyL imaging will be performed at baseline, 8 weeks after ADT initiation, 6 months post SBRT and at recurrence. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi.
Trial: NCT05569252
Drug: DS-1211b
RxNorm normalized name: Uretron DS
DrugBank: DS-1211 (DB17837)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1211b tablet administered once daily in the morning either in the fasted state or with a meal
Trial: NCT04609566
Drug: brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.8 mg/kg given into the vein (IV; intravenously) every 3 weeks
Trial: NCT04609566
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg given intravenously every 3 weeks
Trial: NCT06187402
Drug: LM-24C5
RxNorm normalized name: LM-030
DrugBank: LM-030 (DB18283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05143840
Drug: Asciminib
RxNorm normalized name: Asciminib
DrugBank: Asciminib (DB12597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potent tyrosine kinase inhibitor that displays anti-tumor activity by specifically targeting the ABL myristate-binding pocket (STAMP).
Trial: NCT05143840
Drug: Ascimininb + Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of nilotinib 300mg, once daily, with the goal of attaining MR4.5.
Trial: NCT05143840
Drug: Asciminib + Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of imatinib 300mg, once daily, with the goal of attaining MR4.5.
Trial: NCT05143840
Drug: Asciminib + Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of dasatinib 50mg, once daily, with the goal of attaining MR4.5.
Trial: NCT05543434
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anti-inflammatory, anti-edematous, osseoinductive.
Trial: NCT05018936
Drug: Hetrombopag
RxNorm normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hetrombopag starting at 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
Trial: NCT05216328
Drug: Magnesium hydroxide 724mg
RxNorm normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Information already included in arm/group description.
Trial: NCT04871724
Drug: EDP-938
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive EDP-938 once daily on Days 1 and 14
Trial: NCT04871724
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive fluconazole once daily on Days 5 to 18
Trial: NCT05949931
Drug: Concurrent penpulimab and AVD
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Penpulimab (DB16747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Penpulimab and AVD injection at the same time for a total of 6 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
Trial: NCT05949931
Drug: Sequential penpulimab and AVD
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Penpulimab (DB16747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive penpulimab for 3 cycles; follewed by 6 cycles of AVD; finally, penpulimab for 3 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.